Featured News

  • The Pulmonary Fibrosis Foundation’s Commitment to Equality

    The Pulmonary Fibrosis Foundation is committed to its mission to drive research and act as the trusted resource for individuals afflicted with pulmonary fibrosis. We exist to serve people of every race and background, and we know that the suffering resulting from PF is often accompanied by other painful hardships borne by patients and their loved ones.

  • Pulmonary Fibrosis Foundation Expands Medical Team

    The Pulmonary Fibrosis Foundation (PFF) announced the appointment of three highly respected pulmonologists as senior members of its medical team. The new team members are: Dr. Amy Hajari Case of Piedmont Healthcare (Atlanta); Dr. Sonye Danoff of the Johns Hopkins University School of Medicine (Baltimore); and Dr. Joyce Lee of the University of Colorado Anschutz Medical Campus (Aurora). They will bring a combined 40-plus years of expertise in treating individuals with interstitial lung disease (ILD).

  • The PFF's Letter to CMS

    Pulmonary fibrosis patients are at high-risk of complications related to COVID-19 and need protections that reduce their chance for exposure to the virus. At the same time, many pulmonary fibrosis patients rely on pulmonary rehabilitation (PR) services. PR has been shown to improve many PF patients’ exercise capacity and health-related quality of life. Because there are limited treatment options for PF, pulmonary rehabilitation is all the more essential for helping to maintain PF patients’ health.

  • COVID-19 FAQs

    To limit or prevent the spread of COVID-19, several recommendations have been suggested by the Centers for Disease Control (CDC). Read our FAQ for pulmonary fibrosis patients.

  • PFF COVID-19 Guidance Statement

    The Pulmonary Fibrosis Foundation medical team is actively monitoring the evolving outbreak of the COVID-19 coronavirus to evaluate the potential health implications for the pulmonary fibrosis (PF) community in the USA. Read our Guidance Statement here.

  • PFF Guidance on COVID-19 and FAQs

    The Pulmonary Fibrosis Foundation medical team is actively monitoring the evolving outbreak of the COVID-19 coronavirus to evaluate the potential health implications for the pulmonary fibrosis (PF) community in the USA.

  • 86% of Americans Do Not Know Symptoms of Pulmonary Fibrosis

    Pulmonary Fibrosis Foundation National Awareness Survey reveals little understanding of disease in advance of Rare Disease Week.

  • NIH Awards Major Grant In Pulmonary Fibrosis Research

    The Pulmonary Fibrosis Foundation announced the launch of PRECISIONS, a study that aims to transform the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), by moving it into the era of precision medicine.

  • Three Lakes Partners And Pulmonary Fibrosis Foundation Partner In Fight Against Pulmonary Fibrosis

    Commit To Drive Disease Awareness, Expand Research And Patient Advocacy

  • Medical Centers To Treat Patients With Complex Lung Disease

    Pulmonary Fibrosis Foundation’s Care Center Network Expands To 33 States

  • PULMONARY FIBROSIS PATIENT REGISTRY RESEARCH PRESENTED AT AMERICAN THORACIC SOCIETY CONFERENCE

    The Pulmonary Fibrosis Foundation announced data from four studies exploring the symptoms and treatments associated with this progressive and debilitating form of lung disease.

  • PULMONARY FIBROSIS FOUNDATION UPDATES WARNING ON STEM CELL THERAPIES OUTSIDE CLINICAL TRIALS

    The medical advisory board of the Pulmonary Fibrosis Foundation, the nation’s leading patient education and advocacy organization representing the more than 200,000 Americans with pulmonary fibrosis, has issued an updated statement on the use of stem cell/cell-based therapies.

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >